Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 Norovirus diarrhea in gnotobiotic pigs

Journal of Virology

Volumn 8, Issue 17, 2014, Pages 9728-9743

  Kocher, Jacob ^a   Bui, Tammy ^a   Giri Rachman, Ernawati ^a,b   Wen, Ke ^a   Li, Guohua ^a   Yang, Xingdong ^a   Liu, Fangning ^a,e   Tan, Ming ^c,d   Xia, Ming ^c   Zhong, Weiming ^c   Jiang, Xi ^c,d   Yuan, Lijuan ^a  

^a CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

^b BANDUNG INSTITUTE OF TECHNOLOGY   (Indonesia)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NOROVIRUS VACCINE; PROTEIN VP1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS VACCINE; CAPSID PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CROSS PROTECTION; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DRUG EFFICACY; DUODENUM; EFFECTOR CELL; FEMALE; GNOTOBIOTICS; HELPER CELL; ILEUM; INTESTINAL TISSUE; LYMPHOID TISSUE; MALE; MEMORY T LYMPHOCYTE; NEWBORN; NONHUMAN; NOROVIRUS INFECTION; P PARTICLE; PORCINE MODEL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE ACTIVATION; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS SHEDDING; ANIMAL; CALICIVIRIDAE INFECTIONS; CHILD; DISEASE MODEL; GENETICS; GERMFREE ANIMAL; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; INTRANASAL DRUG ADMINISTRATION; NOROVIRUS; ORAL DRUG ADMINISTRATION; PIG; T LYMPHOCYTE SUBPOPULATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; CALICIVIRIDAE INFECTIONS; CAPSID PROTEINS; CHILD; CROSS PROTECTION; DIARRHEA; DISEASE MODELS, ANIMAL; GERM-FREE LIFE; HUMANS; INTESTINAL MUCOSA; NOROVIRUS; SPLEEN; SWINE; T-LYMPHOCYTE SUBSETS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES; VIRUS SHEDDING;

EID: 84917723840     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01249-14     Document Type: Article

References (60)

1. Patel MM, Hall AJ, Vinje J, Parashar UD. 2009. Noroviruses: a comprehensive review. J. Clin. Virol. 44:1-8. http://dx.doi.org/10.1016/j.jcv.2008.10.009.
2. Hall AJ. 2012. Noroviruses: the perfect human pathogens? J. Infect. Dis. 205:1622-1624. http://dx.doi.org/10.1093/infdis/jis251.
3. Payne DC, Vinje J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, Hall CB, Chappell J, Bernstein DI, Curns AT, Wikswo M, Shirley SH, Hall AJ, Lopman B, Parashar UD. 2013. Norovirus and medically attended gastroenteritis in U.S. children. N. Engl. J. Med. 368:1121-1130. http://dx.doi.org/10.1056/NEJMsa1206589.
4. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe RV. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis. 5:607-625. http://dx.doi.org/10.3201/eid0505.990502.
5. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14:1224-1231. http://dx.doi.org/10.3201/eid1408.071114.
6. Gastanaduy PA, Hall AJ, Curns AT, Parashar UD, Lopman BA. 2013. Burden of norovirus gastroenteritis in the ambulatory setting-United States, 2001-2009. J. Infect. Dis. 207:1058-1065. http://dx.doi.org/10.1093/infdis/jis942.
7. El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, Bargatze RF, Sztein MB, Tacket CO. 2010. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202:1649-1658. http://dx.doi.org/10.1086/657087.
8. Jiang X, Wang M, Wang K, Estes MK. 1993. Sequence and genomic organization of Norwalk virus. Virology 195:51-61. http://dx.doi.org/10.1006/viro.1993.1345.
9. Harrington PR, Vinje J, Moe CL, Baric RS. 2004. Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. J. Virol. 78:3035-3045. http://dx.doi.org/10.1128/JVI.78.6.3035-3045.2004.
10. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, Clement M, Cailleau-Thomas A, Ruiz-Palacois G, Huang P, Jiang X, Le Pendu J. 2002. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 122:1967-1977. http://dx.doi.org/10.1053/gast.2002.33661.
11. Tan M, Jiang X. 2005. The P domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J. Virol. 79:14017-14030. http://dx.doi.org/10.1128/JVI.79.22.14017-14030.2005.
12. Fang H, Tan M, Xia M, Wang L, Jiang X. 2013. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLoS One 8:e63269. http://dx.doi.org/10.1371/journal.pone.0063269.
13. Tamminen K, Huhti L, Koho T, Lappalainen S, Hytonen VP, Vesikari T, Blazevic V. 2012. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology 135:89-99. http://dx.doi .org/10.1111/j.1365-2567.2011.03516.x.
14. Tan M, Jiang X. 2012. The formation of P particle increased immunogenicity of norovirus P protein. Immunology 136:28-29. http://dx.doi.org /10.1111/j.1365-2567.2012.03555.x.
15. Tan M, Fang P, Chachiyo T, Xia M, Huang P, Fang Z, Jiang W, Jiang X. 2008. Noroviral P particle: structure, function and applications in virus- host interaction. Virology 382:115-123. http://dx.doi.org/10.1016/j .virol.2008.08.047.
16. Tan M, Hegde RS, Jiang X. 2004. The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J. Virol. 78:6233-6242. http://dx.doi.org/10.1128/JVI.78.12.6233-6242.2004.
17. Tan M, Huang P, Xia M, Fang PA, Zhong W, McNeal M, Wei C, Jiang W, Jiang X. 2011. Norovirus P particle, a novel platform for vaccine development and antibody production. J. Virol. 85:753-764. http://dx.doi .org/10.1128/JVI.01835-10.
18. Tan M, Jiang X. 2012. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond.) 7:889 - 897. http://dx.doi.org/10.2217/nnm.12.62.
19. Cheetham S, Souza M, Meulia T, Grimes S, Han MG, Saif LJ. 2006. Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J. Virol. 80:10372-10381. http://dx.doi.org/10.1128/JVI.00809-06.
20. Souza M, Cheetham SM, Azevedo MS, Costantini V, Saif LJ. 2007. Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). J. Virol. 81:9183-9192. http://dx.doi.org/10.1128/JVI.00558-07.
21. Souza M, Costantini V, Azevedo MS, Saif LJ. 2007. A human noroviruslike particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 25:8448-8459. http://dx.doi.org/10.1016/j.vaccine.2007.09.040.
22. Bui T, Kocher J, Li Y, Wen K, Li G, Liu F, Yang X, Leroith T, Tan M, Xia M, Zhong W, Jiang X, Yuan L. 2013. Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. J. Gen. Virol. 94(Part 9):2005-2016. http://dx.doi.org/10.1099/vir.0.054080-0.
23. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. 2000. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18:2416-2425. http://dx.doi .org/10.1016/S0264-410X(99)00572-1.
24. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. 2001. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51:81-96. http://dx.doi.org/10.1016/S0169-409X(01)00171-5.
25. Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ. 2012. Glucopyranosyl lipid adjuvant (GLA), a synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One 7:e41144. http://dx.doi.org/10.1371/journal.pone.0041144.
26. Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C. 2006. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 24:3953-3963. http://dx.doi.org/10.1016/j.vaccine.2006.02.024.
27. Ramirez K, Wahid R, Richardson C, Bargatze RF, El-Kamary SS, Sztein MB, Pasetti MF. 2012. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin. Immunol. (Orlando, Fla.) 144:98-108. http://dx.doi.org/10.1016/j.clim.2012.05.006.
28. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM. 2011. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365:2178-2187. http://dx.doi.org/10.1056/NEJMoa1101245.
29. Simmons K, Gambhir M, Leon J, Lopman B. 2013. Duration of immunity to norovirus gastroenteritis. Emerg. Infect. Dis. 19:1260-1267. http://dx.doi.org/10.3201/eid1908.130472.
30. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. 1977. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med. 297:86-89. http://dx.doi.org/10.1056/NEJM197707142970204.
31. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. 2010. Serological correlate of protection against norovirusinduced gastroenteritis. J. Infect. Dis. 202:1212-1218. http://dx.doi.org /10.1086/656364.
32. Zhu S, Regev D, Watanabe M, Hickman D, Moussatche N, Jesus DM, Kahan SM, Napthine S, Brierley I, Hunter RN, III, Devabhaktuni D, Jones MK, Karst SM. 2013. Identification of immune and viral correlates of norovirus protective immunity through comparative study of intracluster norovirus strains. PLoS Pathog. 9:e1003592. http://dx.doi.org/10.1371/journal.ppat.1003592.
33. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. 2005. Cellular and humoral immunity following Snow Mountain virus challenge. J. Virol. 79:2900-2909. http://dx.doi.org/10.1128/JVI.79.5.2900-2909.2005.
34. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. 2003. Humoral, mucosal, and cellular immune responses to oral Norwalk viruslike particles in volunteers. Clin. Immunol. (Orlando, Fla.) 108:241-247. http://dx.doi.org/10.1016/S1521-6616(03)00120-7.
35. Chachu KA, LoBue AD, Strong DW, Baric RS, Virgin HW. 2008. Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog. 4:e1000236. http://dx.doi.org/10.1371/journal.ppat.1000236.
36. Tomov VT, Osborne LC, Dolfi DV, Sonnenberg GF, Monticelli LA, Mansfield K, Virgin HW, Artis D, Wherry EJ. 2013. Persistent enteric murine norovirus infection is associated with functionally suboptimal virus- specific CD8 T cell responses. J. Virol. 87:7015-7031. http://dx.doi .org/10.1128/JVI.03389-12.
37. Kageyama T, Kojima S, Shinohara M, Uchida K, Fukushi S, Hoshino FB, Takeda N, Katayama K. 2003. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. J. Clin. Microbiol. 41:1548-1557. http://dx.doi.org /10.1128/JCM.41.4.1548-1557.2003.
38. Buesa J, Collado B, Lopez-Andujar P, Abu-Mallouh R, Rodriguez Diaz J, Garcia Diaz A, Prat J, Guix S, Llovet T, Prats G, Bosch A. 2002. Molecular epidemiology of caliciviruses causing outbreaks and sporadic cases of acute gastroenteritis in Spain. J. Clin. Microbiol. 40:2854-2859. http://dx.doi.org/10.1128/JCM.40.8.2854-2859.2002.
39. Jiang X, Wang M, Graham DY, Estes MK. 1992. Expression, selfassembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66:6527-6532.
40. Arnold M, Patton JT, McDonald SM. 2009. Culturing, storage, and quantification of rotaviruses. Curr. Protoc. Microbiol. Chapter 15:Unit 15C.3. http://dx.doi.org/10.1002/9780471729259.mc15c03s15.
41. Brito LA, Singh M. 2011. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J. Pharm. Sci. 100:34-37. http://dx .doi.org/10.1002/jps.22267.
42. Meyer RC, Bohl EH, Kohler EM. 1964. Procurement and maintenance of germ-free seine for microbiological investigations. Appl. Microbiol. 12:295-300.
43. Yuan L, Ward LA, Rosen BI, To TL, Saif LJ. 1996. Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J. Virol. 70:3075-3083.
44. Wen K, Li G, Bui T, Liu F, Li Y, Kocher J, Lin L, Yang X, Yuan L. 2012. High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs. Vaccine 30:1198-1207. http://dx.doi.org/10.1016/j.vaccine.2011.11.107.
45. Yuan L, Wen K, Azevedo MS, Gonzalez AM, Zhang W, Saif LJ. 2008. Virus-specific intestinal IFN-γ producing T cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs. Vaccine 26:3322-3331. http://dx.doi.org/10.1016/j.vaccine.2008.03.085.
46. +regulatory cells are the predominant responding regulatory T cells after human rotavirus infection or vaccination in gnotobiotic pigs. Immunology 137:160-171. http://dx.doi.org/10.1111/j .1365-2567.2012.03617.x.
47. Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C, Green KY. 2012. Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30:3580-3586. http://dx.doi.org/10.1016/j.vaccine.2012.03.050.
48. McCabe-Sellers BJ, Beattie SE. 2004. Food safety: emerging trends in foodborne illness surveillance and prevention. J. Am. Diet Assoc. 104:1708-1717. http://dx.doi.org/10.1016/j.jada.2004.08.028.
49. Yang Y, Xia M, Tan M, Huang P, Zhong W, Pang XL, Lee BE, Meller J, Wang T, Jiang X. 2010. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J. Virol. 84:9595-9607. http://dx.doi.org/10.1128/JVI.02614-09.
50. Debbink K, Lindesmith LC, Donaldson EF, Baric RS. 2012. Norovirus immunity and the great escape. PLoS Pathog. 8:e1002921. http://dx.doi .org/10.1371/journal.ppat.1002921.
51. Siebenga JJ, Vennema H, Renckens B, de Bruin E, van der Veer B, Siezen RJ, Koopmans M. 2007. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81:9932-9941. http://dx.doi .org/10.1128/JVI.00674-07.
52. Debbink K, Lindesmith LC, Donaldson EF, Costantini V, Beltramello M, Corti D, Swanstrom J, Lanzavecchia A, Vinje J, Baric RS. 2013. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J. Infect. Dis. 208:1877-1887. http://dx.doi .org/10.1093/infdis/jit370.
53. Iritani N, Seto T, Hattori H, Natori K, Takeda N, Kubo H, Yamano T, Ayata M, Ogura H, Seto Y. 2007. Humoral immune responses against norovirus infections of children. J. Med. Virol. 79:1187-1193. http://dx .doi.org/10.1002/jmv.20897.
54. Rockx B, Baric RS, de Grijs I, Duizer E, Koopmans MP. 2005. Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J. Med. Virol. 77:439-446. http://dx.doi.org/10.1002/jmv.20473.
55. Farkas T, Thornton SA, Wilton N, Zhong W, Altaye M, Jiang X. 2003. Homologous versus heterologous immune responses to Norwalk-like viruses among crew members after acute gastroenteritis outbreaks on 2 US Navy vessels. J. Infect. Dis. 187:187-193. http://dx.doi.org/10.1086/367809.
56. LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, Moe CL, Baric RS. 2006. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24:5220-5234. http://dx.doi.org/10.1016/j.vaccine.2006.03.080.
57. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. 2009. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J. Virol. 83:3212-3227. http://dx.doi.org/10.1128/JVI.01650-08.
58. Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5:e31. http://dx.doi.org/10.1371/journal.pmed .0050031.
59. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. 2012. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J. Virol. 86:1214-1226. http://dx.doi.org/10.1128/JVI.06189-11.
60. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. 2012. The potential economic value of a human norovirus vaccine for the United States. Vaccine 30:7097-7104. http://dx.doi.org/10.1016/j.vaccine.2012.09.040.